WHEN BECTON DICKINSON (BD) ANNOUNCED ITS INTENT to spin off its in vitro diagnostics (IVD) and life sciences units in February, few observers expected a deal to close just five months later. But now that such an agreement has occurred as of July 14, the buyer—Waters Corporation—finds itself dropped into a competitive industry that is […]
Fast, $17.5B Deal Lands Waters Corp. in IVD Market
As Waters merges with BD’s former diagnostics arm, customers should monitor flow cytometry products
- By Janette Wider
- > From the Volume XXXII, No. 11 - August 4, 2025 Issue
- Tags: Abbott Laboratories, Amol Chaubal, BD, BD Biosciences and Diagnostics Solutions, Becton Dickinson, bioanalytical characterization, bioseparation, clia, Danaher, EBITDA, FDA, final rule, flow cytometry, Food and Drug Administration, in vitro diagnostics, IVD, LC-MS, life sciences, liquid chromatography, LTC LLC Healthcare, mass spectrometry, multiplex diagnostics, Qiagen, Remi Health, Reverse Morris Trust, Rob LaCroix, Roche, Thermo Fisher Scientific, Tom Polen, Udit Batra, WAT, Waters Corporation
